Oxford Nanopore Technologies is a pioneering biotechnology company established in 2005 as a spin-out from the University of Oxford. With a workforce of over 1,000 specialists spanning fields such as nanopore science, molecular biology, informatics, engineering, and manufacturing, the company is committed to advancing the boundaries of genomics. Under the leadership of CEO Dr Gordon Sanghera, the company has brought groundbreaking technologies to the global market.

Headquartered at the Oxford Science Park in the UK, Oxford Nanopore operates internationally, with offices in the US, Europe, and Asia, and commercial activity in over 120 countries. In 2019, the company reinforced its capabilities by opening a high-tech manufacturing facility in Oxford.

Oxford Nanopore has developed a unique DNA/RNA sequencing technology that enables real-time analysis of native DNA or RNA strands, with read lengths ranging from short to ultra-long. Its portfolio includes portable tools like the MinION and Flongle, as well as high-throughput systems like GridION and PromethION. These devices cater to diverse research needs — from field studies to population-scale genomics — while maintaining a strong focus on simplicity, speed, and automation in sequencing workflows.